Latest news with #Enhertu
Globe and Mail
3 hours ago
- Business
- Globe and Mail
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AstraZeneca 's AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of $2.17 per share rose 10% year over year on a reported basis and 12% on a constant exchange rate (CER). Total revenues of $14.46 billion rose 12% on a reported basis and 11% at CER, driven by higher product sales and alliance revenues from partnered medicines. Revenues beat the Zacks Consensus Estimate of $14.03 billion. All growth rates mentioned below are on a year-over-year basis and at CER. AZN's Product Sales & Alliance Revenues Among AstraZeneca's various therapeutic areas, Oncology revenues were up 18%, while Cardiovascular, Renal and Metabolism ('CVRM') product sales rose 3%. The Respiratory & Immunology (R&I) segment's sales rose 12%. While Rare disease revenues rose 7%, sales of Vaccines & Immune (V&I) Therapies rose 54%. Sales of other medicines were down 9%. Product sales rose 10% to $13.8 billion, as strong underlying demand trends for its products were partially offset by new manufacturer discounts under Medicare Part D redesign in the United States. Alliance revenues include royalties and profit share from partnered medicines, such as Enhertu and Tezspire, in geographies where its partner books product sales. Alliance revenues rose 35% to $654 million, driven by continued revenue growth from partnered medicines. Alliance revenues included $436 million from Daiichi Sankyo for Enhertu and $155 million of AstraZeneca's share of gross profits in the United States from partner Amgen AMGN for Tezspire. Alliance revenues also included $10 million from partner Daiichi Sankyo for Datroway and $27 million for Beyfortus. AZN records a 50% share of gross profits from Beyfortus' sales in major ex-U.S. markets and 25% of brand revenues from the rest of the world markets received from partner Sanofi SNY. The company also records Beyfortus product sales from products supplied to partner Sanofi under the V&I Therapies segment. AstraZeneca's Key Oncology Drugs Beat Estimates Here, we have discussed the total revenues of its drugs by including Alliance revenues and Collaboration revenues within each revenue figure. In Oncology, Tagrisso recorded revenues of $1.81 billion, up 12% year over year, on strong demand for all indications and in all regions, which more than offset the impact of Medicare Part D redesign and pricing pressure in some European markets. Tagrisso sales beat the Zacks Consensus Estimate as well as our model estimate of $1.75 billion. Lynparza's total revenues rose 11% to $838 million, driven by increased market share/demand growth for all approved indications. The drug's sales beat the Zacks Consensus Estimate of $810 million and our estimate of $788.7 million. AstraZeneca markets Lynparza in partnership with Merck MRK. During the quarter, the company did not record any milestone payment from partner Merck related to the drug. Imfinzi generated sales of $1.46 billion in the quarter, up 26%, driven by strong growth from launch in bladder and lung cancer indications, partially offset by mandatory price reductions in Japan. Imfinzi sales beat the Zacks Consensus Estimate of $1.37 billion and our estimate of $1.3 billion. Sales of Calquence rose 10% to $872 million in the quarter. New breast cancer drug Truqap recorded $170 million in revenues in the second quarter of 2025 compared with $132 million in the previous quarter. Newly approved drug Datroway, for which it has a partnership with Daiichi Sankyo, recorded revenues of $11 million in the quarter compared with $4 million in the first quarter, driven by encouraging initial launch uptake in the United States. The FDA approved the expanded use of Datroway for a second indication — non-small cell lung cancer in June. AZN's CVRM Segment Performance In CVRM, Farxiga recorded product sales of $2.15 billion, up 10%, driven by continued demand growth across chronic kidney disease and heart failure. Farxiga sales beat the Zacks Consensus Estimate of $2.05 billion and our model estimate of $2.06 billion. Brilinta/Brilique sales totaled $215 million in the reported quarter, down 38%, due to the generic launch in Europe and the United States in the second quarter. New drug Wainua recorded $44 million in product sales during the quarter compared with $39 million in the previous quarter, driven by strong launch momentum in the United States and initial launch in ex-U.S. markets. AZN's R&I Segment Performance In R&I, Symbicort sales declined 1% to $715 million due to generic erosion in Europe and competition from triple therapy on the ICS/LABA class of medicines like Symbicort in China. The drug's sales missed the Zacks Consensus Estimate and our model estimate of $726 million and $732.9 million, respectively. Fasenra recorded sales of $502 million in the quarter, up 18% year over year, driven by strong demand growth and market share gains. The recent launch for the EGPA indication also benefited sales in some countries. The drug's sales beat the Zacks Consensus Estimate as well as our model estimate of$467 million. Breztri recorded sales of $283 million, up 20% year over year. Pulmicort sales declined 32% to $106 million. Tezspire recorded total revenues of $261.0 million, up 65% year over year, driven by demand growth and launch uptake in multiple markets. Amgen records product sales in the United States, and AstraZeneca records its share of U.S. gross profits as Alliance revenues. AstraZeneca books product sales in markets outside the United States. New product Airsupra generated $42 million in product sales in the second quarter, compared with $28 million in the previous quarter. New lupus drug, Saphnelo, recorded sales of $167 million, up 48% year over year. AZN's Rare Disease, V&I and Other Segment In the Rare Disease portfolio, Soliris sales fell 22% to $530 million due to conversion to Ultomiris and biosimilar erosion in Europe. Ultomiris revenues amounted to $1.18 billion, up 23%, driven by patient demand, growth in neurology indications, geographic expansions in new markets and continued conversion from Soliris. The impact of Medicare Part D redesign was minimal in the second quarter. In Other Medicines, sales of Nexium declined 11% to $201 million. In V&I Therapies, AstraZeneca recorded $126 million in revenues from Beyfortus, which included alliance revenues mentioned earlier as well as sales of manufactured Beyfortus product to Sanofi. AZN Maintains 2025 Guidance AstraZeneca maintained its financial guidance for 2025. It expects total revenues to grow by a high single-digit percentage at CER. Core EPS is expected to increase by a low double-digit percentage. Our Take on AZN's Results AstraZeneca reported decent second-quarter results, as its earnings matched estimates and revenues beat the same. Sales of almost all key drugs, including Tagrisso, Lynparza, Imfinzi, Farxiga and Fasenra beat estimates. All these drugs have been driving AstraZeneca's top-line growth over the past several quarters, backed by increasing demand trends. Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap also contributed to top-line growth in the second quarter. AstraZeneca also announced an increase in its interim dividend by 3% to $1.03 per share. Shares of the British drugmaker rose around 4% in pre-market trading on Tuesday in response to the strong top-line performance. Year to date, the stock has risen 11.1% compared with the industry 's 3.1% increase. AZN reaffirmed its 2025 guidance. Despite the potential impact from Part D redesign, AstraZeneca expects total revenues to grow by a high single-digit percentage at CER in 2025. Growth momentum in the Oncology and CVRM segments is expected to continue in 2025. However, in Rare Disease, though AstraZeneca expects growth in 2025, it will be at a slower pace than in 2024. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. AstraZeneca expects to generate$80 billion in total revenues by 2030, a significant increase from the $54 billion it generated in 2024. By the said time frame, AstraZeneca plans to launch 20 new medicines, with almost half of these already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. The company is also on track to achieve a mid-30s percentage core operating margin by 2026 Earlier this month, AZN announced plans to invest $50 billion by 2030 to boost manufacturing and R&D in the United States to expand domestic production in response to ongoing tariff pressures under President Donald Trump. AZN's Zacks Rank Currently, AstraZeneca has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Higher. Faster. Sooner. Buy These Stocks Now A small number of stocks are primed for a breakout, and you have a chance to get in before they take off. At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We've combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month. You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days. Download the report free now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report
Yahoo
11-07-2025
- Business
- Yahoo
Cancer Antibody Drug Conjugates Treatment Market Size Clinical Trials FDA Approved Report
Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research Delhi, July 11, 2025 (GLOBE NEWSWIRE) -- Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales and Clinical Trials Insight 2030 Report Finding & Inclusions: Global Cancer Antibody Drug Conjugates Market: 2020 – 2030 Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030 Approved Cancer Antibody Drug Conjugates: 16 Drugs Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Insight On Commercially Approved Antibody Drug Conjugates By Brand Name, Company and Indication Download Report: The global cancer antibody-drug conjugate (ADC) market represents one of the most dynamic and rapidly advancing areas in oncologic therapy. ADCs combine the precision targeting of monoclonal antibodies with potent cytotoxic agents, delivering effective treatment directly to cancer cells while sparing healthy tissue. As of July 2025, nineteen ADCs have been approved worldwide, underscoring both clinical acceptance and regulatory momentum. Key approved ADCs include Enhertu (trastuzumab deruxtecan), which generated over US$ 3.75 billion in 2024 sales, led by its strong performance in HER2-positive cancers. Kadcyla (trastuzumab emtansine) also continues to deliver blockbuster revenue, with approximately US$ 2.3 billion in sales in 2024. Other top-performing ADCs include Adcetris (US$ 1.91 billion), Padcev (US$ 1.59 billion), Trodelvy (US$ 1.32 billion), and Polivy (US$ 1.30 billion). The commercial success of these therapies reflects their differentiated clinical value and growing adoption across multiple oncology indications. The market outlook remains strong, with forecasts projecting the ADC segment to surpass US$ 50 billion by 2030, driven by indication expansion, global market penetration, and sustained innovation. The clinical pipeline features over 500 ADC candidates utilizing diverse payloads, bispecific constructs, and next-generation linker technologies. Trials are being conducted globally, with leadership from US and European pharmaceutical companies and rising activity across the Asia-Pacific region—particularly in China, where domestic ADCs such as Aidixi (disitamab vedotin) have gained approval. Approved ADCs have demonstrated significant impact across different tumor targets. Enhertu and Kadcyla underscore the potential of HER2-directed therapy, while agents like Trodelvy (Trop-2), Polivy (CD79b), and Padcev (Nectin-4) exemplify ADC effectiveness in other solid and hematologic malignancies. Patent protection varies across the field, with many agents maintaining extended market exclusivity through novel payload-linker innovations and optimized delivery mechanisms. The ADC clinical pipeline reveals deep innovation. Over 500 molecules are in development, with trials mapped by company, geography, indication, and phase. This breadth enables stakeholders to track development trends across solid and hematologic cancers, with indications expanding into lung, urothelial, ovarian, and beyond. Company-level insights spotlight R&D activity, with several early-stage ADCs progressing into pivotal trials. Commercially approved ADC brands are profiled thoroughly in our report. Enhertu, Kadcyla, Adcetris, Padcev, Polivy, Trodelvy, and newer agents such as Datroway (datopotamab deruxtecan) and Zynlonta (loncastuximab tesirine) are explored in-depth, analyzing mechanisms, development history, regulatory milestones, and indication-specific adoption. This provides a tactical overview of competitive positioning and licensing trends—especially in Asia-Pacific, where local players are launching biosimilar or region-specific ADCs. Our Global Cancer ADC Market Report delivers a comprehensive, data-driven foundation for stakeholders. It includes sales performance and patent analysis for 19 approved ADCs, pricing strategy insights and dosage regimens, pipeline tracking of 500+ clinical ADCs by indication and trial phase, and brand-by-brand commercial intelligence. This resource empowers pharmaceutical executives, biotech investors, and clinical researchers with the insights needed to navigate a sector poised for exponential growth. As ADC therapy evolves, our report is the strategic compass for development prioritization, portfolio building, and market entry planning—at the frontline of oncology Neeraj Chawla Research Head Kuick Research neeraj@ +91-11-47067990 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
&w=3840&q=100)
First Post
11-07-2025
- Health
- First Post
Major cancer drugs could become cheaper as India considers import duty waiver
The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and trastuzumab deruxtecan (brand Enhertu), used to treat lung and breast cancer, will be fully exempted from customs duty read more India will likely slash the prices of medicines used to treat critical conditions like HIV Aids and cancer as a government panel has recommended waiving off some customs duties on high-impact drugs. News18 has accessed a document of the proposed cuts in prices that are expected to provide relief to patients with cancer and other chronic diseases. The central government has constituted an interdepartmental committee that has suggested customs duty exemptions and concessions for high-impact medical imports. STORY CONTINUES BELOW THIS AD Established in August 2024 by the Drug Controller General of India (DCGI), the panel is headed by Joint Drug Controller R. Chandrashekar and includes representatives from the Indian Council of Medical Research (ICMR), the Department of Pharmaceuticals, and the Directorate General of Health Services (DGHS). Its goal is to make life-saving treatments, such as those for cancer, rare diseases, organ transplants, and advanced diagnostics, much more affordable for Indian patients. More from Health US faces worst measles outbreak in decades amid falling vaccination rates under Trump Which drugs will get cheaper? The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and trastuzumab deruxtecan (brand Enhertu), used to treat lung and breast cancer, will be fully exempted from customs duty. These medicines often cost up to lakhs per dose and have remained inaccessible to patients due to the high import burden. Apart from cancer drugs, the committee has also proposed making several other medicines cheaper, including transplant drugs, critical care medicines, and advanced diagnostic kits that are slapped with heavy import duties and have no equivalent in the Indian market. A second category of essential but widely available drugs has been proposed for a reduced import duty of 5 per cent. This list includes hydroxyurea, used to treat cancer and sickle cell anaemia, and low molecular weight heparin, marketed as Enoxaparin, which is commonly used to prevent and treat blood clots and deep vein thrombosis. Therapies also included Along with life-saving drugs, the document also mentions price cuts for medical therapies to treat rare diseases. Customs duty exemptions might be applied on a group of therapies used to treat conditions such as spinal muscular atrophy, cystic fibrosis, Gaucher disease, Fabry disease, lysosomal storage disorders, and hereditary enzyme deficiencies. Many of these therapies, such as gene-based and enzyme replacement treatments, rank among the most expensive drugs globally, with single courses costing several crores. Notable rare disease drugs on the list include Zolgensma, Spinraza, Evrysdi, Cerezyme, and Takhzyro. These medications are extremely costly and largely beyond the reach of most Indian patients. STORY CONTINUES BELOW THIS AD
Business Insider
03-07-2025
- Business
- Business Insider
British Drugs Giant AstraZeneca Pondering Stock Market Shift to the U.S.
Pharmaceutical giant AstraZeneca (AZN), the U.K.'s most valuable company, is considering moving its stock market listing to the U.S. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. U.K. Restrictions Chief Executive Sir Pascal Soriot, as reported by The Times, has spoken privately about his desire to leave the FTSE 100 behind and head stateside. Soriot is said to be concerned about how quickly Europe is falling behind the U.S. and China when it comes to medicine innovation. He is also known to be frustrated by the restrictions on approvals of new drugs and treatments by the state-owned National Institute for Health and Care Excellence, or NICE – such as breast cancer drug Enhertu. AstraZeneca is no stranger to the U.S., which accounts for over 40% of its $54 billion group revenues. It recently ramped up investment there both to escape tariff hits and as a move away from those U.K. and European restrictions. London Loss The loss of the firm, with a market value of around £160 billion, would be a major blow to the London stock market and will likely meet opposition from some shareholders and the U.K. government. It would follow on the heels of other firms shifting their primary listings to the U.S., such as building materials supplier CRH (CRH). 'America is important to its growth strategy and it could become an even bigger cog in the wheel,' said Dan Coatsworth, investment analyst at AJ Bell. 'The CEO seems frustrated at the lack of financial support to open new laboratories and manufacturing facilities in Europe and might see a full U.S. stock listing as a stepping stone to receiving better treatment stateside.' Is AZN a Good Stock to Buy Now?
Rhyl Journal
02-07-2025
- Health
- Rhyl Journal
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'
